Narasimhan: CAR-T therapy development will shift to an iterative model
Vas Narasimhan · a16z Podcast | The Science and Business of Innovative Medicines · Jan 17, 2019 · at 29:40
Vas Narasimhan, CEO of Novartis, explains how CAR-T cell therapy manufacturing and engineering will transition from bespoke drug development to generational iterations.
0:00 / 0:29exact quote · 29.2s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“I think in the specific example of car T I do think that's, what's going to happen because you have such a complex manufacturing that you're going to have the first generation, let's say of a CD-nineteen card, which is a cart that targets B cell cancers. And you're going to try to then move into a next generation that hopefully has more rapid manufacturing, maybe higher efficacy, and then even more rapid manufacturing. So you're going to get in to that iteration. Now it's not like medical device iteration. I mean, this is still going to take years to do, but you are going to get to that iteration.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Vas Narasimhan
AI outperforms internal human analysts at forecasting Novartis product sales
“The other area, interestingly, in the financial area as well, we find that AI does a great job predicting our free cashflow, predicting a lot of our sales for key products, and it does better than our internal people because it doesn't have the biases and the …”
Viable animal-to-human organ xenotransplantation will arrive within 10 to 20 years
“I think a couple of things will likely come. I think xenotransplantation, I mean, which has been in and out and worked on. And what's interesting is every one of these comes up and down. So, you know, gene therapies, cell therapies popped up in the nineties, k…”
AI in digital health currently offers very little actual impact
“Well, I have to first say, I completely agree about the hype cycle here. I mean, as we've gotten quite scaled and working on digital health and data science, we've learned that there's a lot of talk and very little in terms of actual delivery of impact.”
Real-world evidence cannot replace randomized blinded clinical trials
“The other thing people talk about, but I mean, I'll take a skeptical voice around it, is the ability to use real world evidence to try to get at these things. But as somebody who's worked in clinical trials for most of their time in, in the industry I do belie…”
Wearable sensors have failed to meet clinical trial validation standards
“When I think about, first of all, I would say just in general in sensors is another place where there's been a lot of hype Above what, of expectations. I mean, we've been really trying to explore the use of sensors in clinical trials now for, in my own experie…”
Pharma clinical trial success rates have stayed flat at 5 percent
“And actually, when you look at attrition rates in our industry, really the chances of success that we have, they haven't moved in the last 15 years. Still, when we bring a medicine into human beings, on average, only one out of 20 works.”